Prostate-specific antigen for treatment monitoring - Abstract

Martini-Klinik, Prostatakarzinom-Zentrum, Universitätsklinik Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.

Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.

Article in German.

Written by:
Graefen M, Fröhner M, Wirth M.   Are you the author?

Reference: Urologe A. 2011 Mar;50(3):309-312.
doi: 10.1007/s00120-010-2413-6

PubMed Abstract
PMID: 21365346

UroToday.com Prostate Cancer Section

email news signup